ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1164508 BOSTON, MA

Position in ACAD

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$34,936,869

-$5,198,031 QoQ

Shares Held

1,569,491

+4.5% QoQ

Ownership

0.917%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

10 quarters on record

Voting authority Sole 99.5472417490766.ToString("F0")% Shared 0.ToString("F0")% None 0.45275825092338856.ToString("F0")%

Healthcare · as of Mar 31, 2026

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $1,767,735,657 across 48 Biotechnology names. ACAD ranks #13 (2.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	638,950	$285,316,733
2	INCY	Incyte Corp	2,830,799	$266,434,801
3	EXEL	Exelixis, Inc.	4,834,625	$207,357,066
4	GMAB	Genmab A/S	4,975,324	$133,487,942
5	REGN	Regeneron Pharmaceuticals, Inc.	171,571	$132,562,617
6	HALO	Halozyme Therapeutics, Inc.	1,918,149	$123,969,969
7	RPRX	Royalty Pharma plc	2,010,398	$96,438,792
8	IONS	Ionis Pharmaceuticals Inc	737,859	$55,405,832

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$34,936,869	1,569,491	+4.5%	Shares	Defined	2026-05-14
2025-12-31	$40,134,900	1,502,617	-8.9%	Shares	Defined	2026-02-13
2025-09-30	$35,186,757	1,648,864	+390.1%	Shares	Defined	2025-11-13
2025-06-30	$7,256,967	336,438	+512.8%	Shares	Defined	2025-08-13
2023-09-30	$1,144,136	54,901	-10.1%	Shares	Defined	2023-11-14
2022-06-30	$860,884	61,099	+901.6%	Shares	Defined	2022-08-15
2020-12-31	$326,106	6,100	-95.8%	Shares	Defined	2021-02-12
2020-09-30	$5,930,141	143,761	-49.8%	Shares	Defined	2020-11-12
2020-06-30	$13,868,914	286,134	+767.1%	Shares	Defined	2020-08-12
2020-03-31	$1,394,250	33,000	—	Shares	Defined	2020-05-15
No filing history on record for this holder in this stock.